Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Keyphrases

• A1 Receptor 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Receptor Agonist 100%
• Glucagon-like 100%
• GLP-1 Receptor Agonist 100%
• Treatment Potential 100%
• Treatment Options 33%
• Adverse Events 16%
• Hypoglycemia 16%
• Insulin 16%
• Hemoglobin A1c (HbA1c) 16%
• Type 2 Diabetic Patients 16%
• Nausea 16%
• Fasting Plasma Glucose 16%
• Gastric Emptying 16%
• Glucagon Secretion 16%
• Insulin Secretion 16%
• Phase II Trial 16%
• Gastrointestinal Distress 16%
• Basal Insulin 16%
• Glucagon-like peptide-1 (GLP-1) 16%
• Sulfonylurea 16%
• Satiety 16%
• Co-formulation 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Glucagon Like Peptide 1 Receptor Agonist 100%
• Adverse Event 14%
• Hypoglycemia 14%
• Hemoglobin A1c 14%
• Nausea 14%
• Glucagon 14%
• Glucagon-Like Peptide-1 14%
• Gastrointestinal Symptom 14%
• Sulfonylurea 14%